Phase 2RecruitingPriority 3 · Moderate priorityNCT05833893
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Plain-language summary
This Phase 2 trial is evaluating XPO1 inhibitor as a treatment for people newly diagnosed with NK/T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 14 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
XPO1 inhibitor (DRUG): COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
- Drugs / treatments
- XPO1 inhibitor
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details